Showing results (301-310 of 548) with videos related to

Sort By:
Pageof 55
Journal of Drugs in Dermatology : JDD|January 28, 2020
Topical Agents for the Treatment of Atopic DermatitisLawrence F. Eichenfield, Thomas Luger, Kim Papp, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|March 14, 2023
Burden of Disease and Unmet Needs in Atopic Dermatitis: Results From a Patient SurveyJonathan I Silverberg, Jennifer A Mohawk, Joshua Cirulli, et al.
Dermatologic Therapy|October 21, 2022
Baricitinib 2 mg for the treatment of atopic dermatitis in North America: Long-term efficacy and patient-reported outcomesEric Simpson, April Armstrong, Mark Boguniewicz, et al.
The British Journal of Dermatology|June 20, 2022
Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study: Classification: EpidemiologyMaria C Schneeweiss, Julien Kirchgesner, Richard Wyss, et al.
Annals of Clinical and Laboratory Science|April 28, 2010
Green tea (Camelia sinensis) suppresses B cell production of IgE without inducing apoptosisEhab Hassanain, Jonathan I Silverberg, Kevin B Norowitz, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 17, 2020
Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis: A phase 2b randomized studyJonathan I Silverberg, Emma Guttman-Yassky, Melinda Gooderham, et al.
American Journal of Clinical Dermatology|October 20, 2022
Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III StudiesLisa Bloudek, Lawrence F Eichenfield, Jonathan I Silverberg, et al.
JAMA Dermatology|May 12, 2021
Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical TrialsJonathan I Silverberg, Eric L Simpson, Andreas Wollenberg, et al.
The British Journal of Dermatology|January 18, 2022
The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trialsGil Yosipovitch, Kim Papp, Seth Forman, et al.
Annals of Clinical and Laboratory Science|February 10, 2009
IgE anti-varicella zoster virus and other immune responses before, during, and after shinglesTamar A Smith-Norowitz, Joby Josekutty, Hadar Lev-Tov, et al.
Pageof 55